The assessment of efficacy and safety of Irreversible Electroporation(IRE) to treat hepatic malignancies
Phase 2
Recruiting
- Conditions
- Hepatocellular carcinoma, metastatic liver cancer, cholangiocarcinoma
- Registration Number
- JPRN-UMIN000014522
- Lead Sponsor
- Tokyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1. Uncontrolled infection, 2. Heart failure, coronary artery disease or arrhythmia in progress, active implantable devices (eg pacemaker), 3. Pregnant women or women of childbearing potential not using an acceptable method of contraception, 4. Patient's disability to stop anticoagulant and antiplatelet therapy, 5. In the opinion of the researcher, anyone who cannot follow the calender of vist and asessment of the Protocol, 6. Patient received systemic chemotherapy within 4 weeks of treatment with the IRE NanoKnife,
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method